Edesa Biotech Inc (EDSA)

$1.83 -0.13 (-6.63%)
Market Cap 12.85M
Revenue (ttm) 0.00
Net Income (ttm) -6.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 40,000
Avg Vol 20,048
Day's Range N/A - N/A
Shares Out 7.02M
Stochastic %K 0%
Beta 0.41
Analysts Strong Sell
Price Target $19.00

Latest News on EDSA

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

May 14, 2025, 4:15 PM EDT - 24 days ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Apr 28, 2025, 4:30 PM EDT - 5 weeks ago

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Edesa Biotech Announces Chief Financial Officer Transition

Apr 4, 2025, 4:15 PM EDT - 2 months ago

Edesa Biotech Announces Chief Financial Officer Transition

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Feb 14, 2025, 4:15 PM EST - 4 months ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Feb 13, 2025, 7:00 AM EST - 4 months ago

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Edesa Biotech Reports Fiscal Year 2024 Results

Dec 13, 2024, 4:30 PM EST - 6 months ago

Edesa Biotech Reports Fiscal Year 2024 Results

Edesa Biotech's Founder Makes Strategic Investment in the Company

Oct 31, 2024, 8:15 AM EDT - 7 months ago

Edesa Biotech's Founder Makes Strategic Investment in the Company

Edesa Biotech Announces Upcoming Conference Schedule

Oct 21, 2024, 8:15 AM EDT - 8 months ago

Edesa Biotech Announces Upcoming Conference Schedule

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Sep 13, 2024, 7:38 PM EDT - 9 months ago

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Aug 9, 2024, 4:20 PM EDT - 10 months ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Jun 24, 2024, 8:20 AM EDT - 1 year ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

May 10, 2024, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Edesa Biotech to Participate in Upcoming Investor Conferences

Apr 2, 2024, 9:00 AM EDT - 1 year ago

Edesa Biotech to Participate in Upcoming Investor Conferences

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Mar 21, 2024, 4:30 PM EDT - 1 year ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Mar 7, 2024, 8:45 AM EST - 1 year ago

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Mar 4, 2024, 4:30 PM EST - 1 year ago

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Feb 9, 2024, 4:15 PM EST - 1 year ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Jan 4, 2024, 4:15 PM EST - 1 year ago

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Edesa Biotech Reports Fiscal Year 2023 Results

Dec 15, 2023, 4:10 PM EST - 1 year ago

Edesa Biotech Reports Fiscal Year 2023 Results

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Nov 20, 2023, 4:05 PM EST - 1 year ago

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 26, 2023, 4:05 PM EDT - 1 year ago

Edesa Biotech to Present at Dermatology Drug Development Summit

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Oct 25, 2023, 9:10 AM EDT - 1 year ago

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Oct 12, 2023, 12:15 PM EDT - 1 year ago

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Oct 12, 2023, 12:10 PM EDT - 1 year ago

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Edesa Biotech Announces One-for-Seven Reverse Share Split

Oct 10, 2023, 9:00 AM EDT - 1 year ago

Edesa Biotech Announces One-for-Seven Reverse Share Split

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Sep 28, 2023, 8:15 AM EDT - 1 year ago

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Aug 9, 2023, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Jul 26, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Jun 28, 2023, 7:55 AM EDT - 2 years ago

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 27, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Jun 15, 2023, 8:00 AM EDT - 2 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

May 11, 2023, 4:30 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Edesa Biotech to Participate in Swiss Biotech Day

Apr 20, 2023, 8:30 AM EDT - 2 years ago

Edesa Biotech to Participate in Swiss Biotech Day

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Apr 4, 2023, 8:45 AM EDT - 2 years ago

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Mar 23, 2023, 4:30 PM EDT - 2 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Mar 16, 2023, 4:10 PM EDT - 2 years ago

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Mar 15, 2023, 8:10 AM EDT - 2 years ago

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Feb 10, 2023, 9:00 AM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Feb 1, 2023, 8:15 AM EST - 2 years ago

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

Jan 17, 2023, 8:30 AM EST - 2 years ago

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Dec 20, 2022, 8:30 AM EST - 2 years ago

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Edesa Biotech Reports Fiscal Year 2022 Results

Dec 16, 2022, 9:00 AM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2022 Results

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

Dec 2, 2022, 8:00 AM EST - 2 years ago

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Nov 3, 2022, 9:00 AM EDT - 2 years ago

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Sep 30, 2022, 8:00 AM EDT - 2 years ago

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

Sep 8, 2022, 4:30 PM EDT - 2 years ago

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

Sep 7, 2022, 8:00 AM EDT - 2 years ago

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

Aug 12, 2022, 4:30 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

Aug 3, 2022, 8:15 AM EDT - 3 years ago

Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

Edesa Biotech to Present at ARDS Drug Development Summit

Jul 11, 2022, 8:30 AM EDT - 3 years ago

Edesa Biotech to Present at ARDS Drug Development Summit